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INTRODUCTION 
 
Nociceptors are specialized nerve endings which detect potentially harmful stimuli and 
transmit them to the central nervous system. Cutaneous nociceptive primary afferents can be 
classified based on their axons as myelinated, fast-conducting Aδ nociceptors and 
unmyelinated slowly-conducting C nociceptors. Concerning phasic stimuli, the previous are 
responsible for the fast, sharp component of pain sensation, whereas the latter generate the 
second, slower, diffuse and blunt component. Based on their sensitivity, a considerable 
fraction of nociceptors are polymodal i.e. sensitive to noxious heat and mechanical stimuli as 
well as endogenous and exogenous chemical substances. 
1. CAPSAICIN-SENSITIVE NOCICEPTORS 
Capsaicin, the pungent compound of chilli pepper has played an outstanding role in the 
investigation of nociceptive primary afferents as a selective test agent. Capsaicin-sensitive 
sensory neurons in the skin are polymodal nociceptors which comprise the majority of C and 
Aδ nociceptors. Capsaicin selectively excites these fibres and at higher concentrations and 
upon longer exposure activation is followed by a persistent functional blockade. This process 
results in a decreased responsiveness of the neuron to all stimuli; however, selectivity ensures 
that other sensory modalities (touch, cold sensitivity, taste etc.) remain intact (Jancsó, 1960; 
Szolcsányi, 1977).  
Orthodromic or antidromic stimulation of capsaicin-sensitive nociceptors elicits 
vasodilatation and plasma protein extravasation in the innervated area. This phenomenon is 
denominated neurogenic inflammation (Jancsó et al., 1967; 1968) which is induced by 
neuropeptides released by exocytosis from the capsaicin-sensitive nerve endings, such as 
tachykinins (substance P, neurokinin A and B) and calcitonin gene-related peptide (CGRP) 
(Maggi, 1995). Capsaicin-sensitive nerves have therefore a dual function: their efferent 
function is the transmission of action potentials from the periphery to the central nervous 
system, whereas neuropeptides released from the peripheral nerve endings mediate a local 
effector function (Szolcsányi, 1996). Nerve endings also contain neuropeptides other than 
tachykinins and CGRP, e.g. somatostatin which is also liberated upon activation (Szolcsányi 
et al., 1998a,b). 
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2. THE CAPSAICIN VR1/TRPV1 RECEPTOR 
The VR1/TRPV1 receptor identified as capsaicin’s receptor was the first heat sensitive ion 
channel to be discovered (Caterina et al., 1997). Besides capsaicin, noxious heat stimuli (> 43 
°C), low pH, other exogenous irritants (e.g. resiniferatoxin) and endogenous mediators 
(anandamide, lipoxygenase products, N-oleoyl-dopamine) are capable of activating the 
receptor. It can be considered therefore an integrator molecule of different physical and 
chemical painful stimuli (Tominaga et al., 1998). When the receptor is activated, the opening 
of the channel pore leads to an influx of Na+ and Ca2+ ions which depolarize the nerve ending 
and eventually contribute to action potential formation, and Ca2+ ions also induce exocytosis 
of stored neuropeptides.  
3. ROLE OF THE TRPV1 RECEPTOR IN THE SENSITIZATION OF NOCICEPTORS 
Tissue injury or inflammation induces hyperalgesia, i.e. enhanced pain sensation which by 
definition implies that the stimulus intensity–pain sensation curve is shifted to the left and its 
maximum is increased. A major component of the development of thermal hyperalgesia is the 
sensitization of the peripheral endings of nociceptive afferents during which their threshold 
decreases and suprathreshold stimuli evoke larger responses. A possible mechanism of heat 
sensitization is that sensitivity of the TRPV1 receptor is increased due to phosphorylation. 
There are more and more available data concerning that mediators capable of sensitizing 
nociceptors to heat (bradykinin, prostaglandins, ATP, serotonin etc.) lead to enhanced heat 
responsiveness by activating signal transduction pathways involving protein kinases (protein 
kinase C – PKC, protein kinase A – PKA) which phosphorylate the TRPV1 receptor 
(Tominaga et al., 2001; Sugiura et al., 2002; Moriyama et al., 2005). Recent reports show that 
various lipoxygenase products are able to excite directly the TRPV1 receptor (Hwang et al., 
2000). The importance of TRPV1 receptor is further supported by the finding that no 
inflammatory thermal hyperalgesia was found in mice lacking the receptor (Caterina et al., 
2000; Davis et al., 2000). In conclusion, TRPV1 receptor-expressing neurons are potential 
peripheral targets for the development of new analgesic drugs.  
4. ANTI-INFLAMMATORY AND ANTINOCICEPTIVE EFFECT OF SOMATOSTATIN 
RELEASED FROM CAPSAICIN-SENSITIVE NERVE ENDINGS 
Tachykinins and CGRP released from capsaicin-sensitive fibres induce local inflammation in 
the innervation area, somatostatin, however, enters the circulation and exerts a systemic anti-
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inflammatory (Szolcsányi et al., 1998a,b) and antinociceptive effect (Helyes et al., 2000). 
Besides the afferent and local efferent functions, capsaicin-sensitive neurons have therefore a 
systemic, neurohormonal regulatory or “sensocrine” function (Thán et al., 2000).  
5. CANNABINOID RECEPTORS AND THEIR AGONISTS: NEW TARGETS OF 
ANALGESIA 
The first identified endogenous cannabinoid, anandamide binds mainly to cannabinoid CB1 
receptors which are found in large numbers in the central nervous system in areas of afferent 
nociceptive pathways and descending inhibitory pathways as well. This indicates that they 
play a role in the central modulation of pain perception (Pertwee, 2001). The presence of CB1 
receptors was also shown on primary afferents which can mediate a potential peripheral 
antinociceptive effect of cannabinoids. CB2 receptor expression was previously described on 
non-neuronal cells which could be responsible for the immunomodulatory effect of 
cannabinoids but there are data pointing to the existence of further, CB2-like receptors which 
also participate in the control of pain transmission (Calignano et al., 1998). 
 
AIMS 
 
Our experiments aimed at the in vivo investigation of potential new targets of analgesia 
located on TRPV1 receptor-expressing neurons using animal models of nociception and 
testing new compounds which act on these targets. Our goals were the following: 
I. Investigating the effect of endogenously occurring cannabinoids, anandamide and 
palmitoyl-ethanolamide on TRPV1 receptor stimulation-induced sensory neuropeptide 
release and on neuropathic mechanical hyperalgesia. 
II. Investigating the antinociceptive effects of the stable and potent heptapeptide 
somatostatin receptor agonist TT-232. 
III. Comparing wild-type and TRPV1 receptor gene deficient mice in acute and chronic 
nociceptive models in vivo. 
IV. Developing a reliable, new thermonociceptive test based on measurement of the heat 
threshold temperature. 
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I. INHIBITORY EFFECT OF ANANDAMIDE (ANA) AND PALMITOYL-
ETHANOLAMIDE (PEA) ON RESINIFERATOXIN-INDUCED SENSORY 
NEUROPEPTIDE RELEASE IN VIVO AND NEUROPATHIC HYPERALGESIA  
 
Anandamide (ANA) was shown to have antinociceptive activity via CB1 receptor stimulation 
in various in vivo animal models and it also effectively diminished inflammatory heat and 
mechanical hyperalgesia (Calignano et al., 1998; Jaggar et al., 1998; Richardson et al., 1998). 
Palmitoyl-ethanolamide (PEA), another endogenous cannabinoid thought to act on a 
peripheral CB2-like receptor, was also effective in different nociceptive tests (Calignano et al., 
1998, 2001; Jaggar et al., 1998). 
Anandamide is also able to activate TRPV1 receptors in vitro (Zygmunt et al., 1999; Smart et 
al., 2000), although the in vivo role and relevance of this effect is subject to a debate. The 
disagreement is based on the fact that CB1 and TRPV1 receptors are expressed by the same 
group of small neurons (Ahluwalia et al., 2000) and the concentration needed to excite 
TRPV1 receptors is orders of magnitude higher than the level which exerts an inhibitory 
effect on sensory neurons via CB1 receptors (Szolcsányi, 2000a,b). 
METHODS 
1. Measurement of resiniferatoxin-induced CGRP and somatostatin release in vivo: In 
anaesthetized rats resiniferatoxin was injected (RTX, 0.6 µg/kg i.v.) to evoke neuropeptide 
release which was measured from arterial blood samples collected 5 min after injection. 
Animals were pretreated with different doses of ANA or PEA (10 or 100 µg/kg i.v.) and CB1 
or CB2 receptor antagonists were applied (SR141716A or SR144528, 100 µg/kg i.v.) 10 min 
before the respective cannabinoid treatment. CGRP and somatostatin concentrations were 
determined from the plasma by sensitive radioimmunoassay (RIA) methods. 
2. Partial sciatic nerve ligation-induced (traumatic) neuropathic mechanical 
hyperalgesia (Seltzer-model): The mechanonociceptive threshold of rats was measured with 
the Randall-Selitto test. The animal’s hind paw was inserted between the cone-shaped pushers 
of the analgesimeter equipment which exerted a continuously increasing force on the limb. 
The force at which the animal withdrew its paw was considered as mechanonociceptive 
threshold. Under anaesthesia, 1/3-1/2 part of the sciatic nerve was ligated unilaterally. One 
week later the effect of ANA or PEA (100 µg/kg i.p.) on the developed hyperalgesia was 
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investigated. CB1 and/or CB2 receptor antagonist (SR141716A or SR144528, 3 mg/kg i.p.) 
was administered 30 min prior to ANA or PEA treatment. 
RESULTS 
1. Effect of ANA and PEA on plasma CGRP and somatostatin concentrations: RTX (0.1-
3 µg/kg i.v.) dose-dependently increased plasma CGRP and somatostatin levels. Basal 
concentrations of neuropeptides were influenced neither by ANA, nor by PEA, however, 
RTX-induced CGRP and somatostatin release was dose-dependently diminished by ANA 
which was inhibited by pretreatment with the CB1 receptor antagonist SR141617A (100 µg/kg 
i.v.). Likewise, PEA dose-dependently decreased sensory neuropeptide release evoked by 
RTX injection.  
2. Effect of ANA and PEA on neuropathic mechanical hyperalgesia following partial 
sciatic nerve lesion: Seven days following partial ligation of the sciatic nerve, 
mechanonociceptive threshold of the animals decreased by 29.7 ± 0.6%. ANA treatment (100 
µg/kg i.p.) completely abolished hyperalgesia. Pretreatment with the CB1 receptor antagonist 
SR141617A (3 mg/kg i.p.) by itself enhanced hyperalgesia by 37.1% and totally inhibited the 
antihyperalgesic action of subsequent ANA injection. PEA (100 µg/kg i.p.) diminished 
hyperalgesia by 79.4% and this effect was prevented by the CB2 receptor antagonist 
SR144528 (3 mg/kg i.p.). Similarly to the CB1 receptor antagonist, this compound also 
increased the threshold drop by 47.5%. Combination of the two antagonists, however, did not 
produce an additive effect on the aggravation of hyperalgesia.  
CONCLUSIONS 
Our results have demonstrated that both anandamide (ANA) and palmitoyl-ethanolamide 
(PEA) inhibited the sensory neuropeptide release in vivo induced by injection of the TRPV1 
receptor agonist RTX, via CB1 and CB2-like receptors, respectively, while they failed to 
influence basal plasma CGRP and somatostatin levels. The potential TRPV1 receptor-
activating effect of ANA is likely to be counteracted by that it binds and activates CB1 
receptors on the same nerve endings with higher affinity. 
Both cannabinoid agonists effectively decreased traumatic neuropathic mechanical 
hyperalgesia, likewise by activating CB1 and CB2-like receptors, respectively. One possible 
mechanism of this effect is that they inhibit sensory neuropeptide release from capsaicin-
sensitive primary afferents. Antagonists of the CB1 and CB2 receptors alone or in combination 
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aggravated mechanical hyperalgesia which indicates that endocannabinoids exert a tonic 
inhibitory effect in neuropathy which alleviates hyperalgesia.  
In conclusion, cannabinoid receptor agonists – especially selective CB2 receptor agonists 
lacking central effects – offer a new therapeutic possibility for the treatment of neuropathic 
pain. 
 
II. ANALGESIC EFFECT OF TT-232, A HEPTAPEPTIDE SOMATOSTATIN 
ANALOGUE, IN ACUTE PAIN MODELS OF THE RAT AND THE MOUSE AND IN 
STREPTOZOTOCIN-INDUCED DIABETIC MECHANICAL ALLODYNIA 
 
The systemic anti-inflammatory and antinociceptive effect of somatostatin released upon 
activation of capsaicin-sensitive nerves makes possible the development of novel, 
peripherally-acting anti-inflammatory and analgesic drugs. Native somatostatin is not suitable 
for this therapeutic use because due to its widespread physiological roles it affects several 
endocrine and gastrointestinal functions in the body and furthermore, its plasma half-life is 
very short (T1/2= 3 min). 
Among the five somatostatin receptor subtypes (sst1-5) sst1 and sst4 receptors mediate no 
endocrine effects, however, they are expressed by sensory neurons which makes them 
therefore potential selective targets. In our department investigation of stable somatostatin 
analogues lacking endocrine side effects has recently been started. The heptapeptide TT-232 
(D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-NH2) synthesized by the Peptide-Biochemistry 
Research Group of the Hungarian Academy of Sciences – which otherwise has a potent 
antiproliferative effect – did not influence growth hormone and gastrine secretion (Kéri et al., 
1996). TT-232 mainly binds to sst4 receptors (Helyes et al., 2005). It effectively decreased 
sensory neuropeptide release in vivo and potently inhibited neurogenic and non-neurogenic 
inflammation in various models (Helyes et al., 2001; Pintér et al., 2002). It diminished 
Complete Freund’s Adjuvant (CFA)-induced joint swelling and mechanical hyperalgesia 
(Helyes et al., 2004) and traumatic neuropathic hyperalgesia as well (Pintér et al., 2002).  
METHODS 
1. Formalin test: On rats, nocifensive reaction was evoked by intraplantar injection of 
formalin (2.5%, 50 µl i.pl.) which appears in two phases: the first phase lasting from 0-5 min 
and the second from 20-45 min after injection. Various doses of TT-232 (20-80 µg/kg) were 
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administered intraperitoneally (0.1 ml/100 g i.p.) 30 min before formalin injection and the 
effect of the drug was compared to a solvent-treated group. Quantitative evaluation of the 
spontaneous nocifensive behaviour was made by the following formula: (2x duration of paw 
lickings + 1x duration of paw liftings)/observation period (Composite Pain Score – CPS). 
2. Phenylquinone-induced abdominal constriction (“writhing”) test: Abdominal 
constrictions were induced by intraperitoneal phenylquinone injection (0.02%, 0.2 ml) which 
is considered a model of visceral nociception. TT-232 was administered subcutaneously 30 
min before (5-200 µg/kg s.c.). The number of abdominal constrictions was counted in a 20-
min period following phenylquinone injection and results were compared to a solvent-treated 
group. 
3. Measurement of the noxious heat threshold and resiniferatoxin-induced thermal 
hyperalgesia: The noxious heat threshold of rats was determined by an increasing-
temperature hot plate. The animal was placed on the metal plate with a built-in heating unit 
which was heated up afterwards at an even rate from room temperature until the rat showed 
nocifensive reaction and the corresponding plate temperature was regarded as heat threshold. 
After control measurements, animals were treated with TT-232 (10-200 µg/kg i.p.), 
measurements were repeated 30 min later and results were compared to the initial control 
thresholds. In another series of experiments, thermal hyperalgesia was evoked by intraplantar 
resiniferatoxin (RTX, 0.05 nmol i.pl.) and threshold determinations were repeated 5, 10, 15 
and 20 min after injection. Different doses of TT-232 (5-100 µg/kg i.p.) were administered 10 
min prior to RTX. On each occasion, half of the group was treated with the vehicle which 
allowed comparisons to an actual solvent control. 
4. Measurement of diabetic neuropathic mechanical allodynia: Experimental diabetes 
mellitus was generated by 50 mg/kg i.v. streptozotocin in rats. Two weeks later, blood 
glucose levels were measured from samples taken from the tail vein with an Accu-Check 
glucometer (Roche) and only animals with a level higher than 15 mmol/l were included in the 
further studies. Mechanonociceptive thresholds of freely moving rats were determined by a 
dynamic plantar aesthesiometer (Ugo Basile). This equipment has a blunt needle which is 
pushed to the plantar surface of the paw with a continuously increasing force at a preset rate 
until the animal withdraws its paw. At this point the needle falls to its initial position and 
mechanonociceptive threshold is read on the display. After diabetes was established, 
thresholds were measured weekly until mechanical allodynia developed. Animals were treated 
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then with various doses of TT-232 (2.5-100 µg/kg i.p.) and threshold measurements were 
repeated 30 min later. 
RESULTS 
 1. Effect of TT-232 on formalin-evoked nocifensive reactions: The first phase of formalin-
evoked nocifensive reaction was only inhibited significantly by the 80 µg/kg i.p. dose based 
on the evaluation of CPS. In the second phase TT-232 showed a bell-shaped dose-response 
curve, as the doses of 40 and 80 µg/kg i.p. had significant antinociceptive effect but 160 
µg/kg failed to decrease CPS. Diclofenac used as a reference drug only inhibited nocifensive 
behaviour in the second phase at a dose of 50 mg/kg i.p.  
2. Effect of TT-232 on phenylquinone-evoked abdominal constrictions: TT-232-
pretreatment (10-200 µg/kg s.c.) significantly diminished the number of writhing movements 
induced by i.p. phenylquinone injection, however, no dose-response relationship could be 
established. Doses of 20 and 200 µg/kg produced the maximum inhibition (70 and 75% 
percentage inhibition), while the effect of doses in between resulted in a bell-shaped dose-
response curve, similarly to that observed in the formalin test.  
3. Effect of TT-232 on the noxious heat threshold and on resiniferatoxin-induced 
thermal hyperalgesia: Control heat threshold of rats was 44.5 ± 0.2 °C. TT-232 significantly 
increased the heat threshold at a dose range of 20-200 µg/kg, a clear-cut dose-dependent 
relationship was not seen in this test either. The maximal increase (1.48 ± 0.4 °C) was 
produced by the 200 µg/kg i.p. dose. 
Intraplantar resiniferatoxin evoked a 7.39 ± 1.3 °C drop of heat threshold 5 min after 
injection. Pretreatment with TT-232 significantly decreased thermal hyperalgesia at doses 
between 10-50 µg/kg i.p., the effect of a higher, 100 µg/kg dose, however, was not 
significant. 
4. Effect of TT-232 on diabetic neuropathic mechanical allodynia: Mechanonociceptive 
threshold decreased by 28.6 ± 3.1% 5 weeks after streptozotocin treatment. TT-232 
significantly diminished mechanical allodynia at doses of 10, 20 and 100 µg/kg i.p., among 
which 20 µg/kg exerted the maximal, 54% inhibition. The mechanical threshold of naïve rats 
was not influenced by 20 µg/kg i.p. TT-232.  
 9
CONCLUSIONS 
Our results have demonstrated that the peripherally-acting somatostatin receptor agonist TT-
232 had a pronounced analgesic effect in nociceptive processes of various origins, in rats and 
mice as well. The effects of low doses of the compound were detectable in the conventionally 
used chemonociceptive tests, the novel thermonociceptive test and the diabetic 
polyneuropathy model. In the formalin test TT-232 proved to be approximately 1000 times 
more potent than diclofenac, while in the thermonociceptive tests – compared to our previous 
results (Almási et al., 2003) – it was 300 times more potent than morphine or diclofenac. The 
advantage of TT-232 is that due to its selective target of action it lacks the side effects which 
could appear as a consequence of somatostatin’s widespread actions. Unwanted effects are 
also reduced by the fact that it does not penetrate the blood-brain barrier. TT-232 is a 
promising candidate to be a novel analgesic drug with a broad profile which includes therapy-
resistant neuropathic conditions.  
 
III. INVESTIGATION OF THE ROLE OF TRPV1 RECEPTORS IN ACUTE AND 
CHRONIC NOCICEPTIVE PROCESSES USING GENE-DEFICIENT MICE 
 
The investigation of the roles of TRPV1 receptor-expressing polymodal nociceptors started 
with experiments on capsaicin’s selective excitatory and consequent blocking effects. 
Examining the desensitizing action of capsaicin, however, only provides information on the 
functions of the whole fibre but not the receptor itself.  
The use of the majority of receptor antagonists (capsazepine, ruthenium red, iodo-
resiniferatoxin – I-RTX) can be impaired by problems with selectivity (Docherty et al., 1997; 
Liu & Simon, 1997) and in vivo efficacy (Jakab et al., 2005) and furthermore I-RTX may 
potentially act as an agonist if it is converted into RTX in the body.  
Cloning the TRPV1 receptor opened the way to the generation and in vivo investigation of 
gene-deleted (knockout) mice (Davis et al., 2000; Caterina et al., 2000). Results showed that 
heat sensitivity of untreated knockout mice did not differ from the wild-type counterparts 
which was surprising given that capsaicin-desensitized animals had higher heat thresholds 
(Szolcsányi, 1985; Szolcsányi, 1987). However, inflammatory thermal hyperalgesia did not 
develop in the absence of the receptor which indicates that heat sensitization of nociceptors 
requires the TRPV1 receptor.  
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METHODS 
Animals: In these experiments TRPV1 receptor gene deficient (TRPV1-/-) and wild-type mice 
(TRPV1+/+) were used.  
1. Phorbolesther-induced acute chemonociception (PMA test): Intraplantar injection of the 
protein kinase C (PKC) activator phorbolesther, phorbol 12-myristate 13-acetate (PMA, 10 
µg/ml, 20 µl) was used to induce nocifensive behaviour which was observed during 45 min 
after injection. For quantitative evaluation of the test, the time spent licking and lifting of the 
paw was measured.  
2. Formalin test: Intraplantar injection of formalin (2.5%, 20 µl i.pl.) was used to induce 
nocifensive behaviour which appears in two phases: the first phase lasting from 0-5 min and 
the second from 20-45 min after injection. For quantitative evaluation of the test, the time 
spent licking and lifting of the paw was measured. 
3. Heat injury-induced thermal and mechanical hyperalgesia: Noxious heat threshold of 
mice was measured by an increasing-temperature hot plate and in another group of animals 
mechanonociceptive threshold was determined by a dynamic plantar aesthesiometer (Ugo 
Basile). After control measurements, under ether anaesthesia one of the hind paws was 
immersed into a 51 °C water bath for 15 sec and measurements were repeated afterwards.  
4. Inflammatory mechanical hyperalgesia evoked by intraplantar carrageenan: 
Mechanonociceptive thresholds of mice were determined by the dynamic plantar 
aesthesiometer. Intraplantar injection of carrageenan (3%, 100 µl) was applied to induce 
inflammation of one of the hind limbs. Thresholds were measured again 3 hours later.  
5. Streptozotocin-induced diabetic polyneuropathy: Experimental diabetes mellitus was 
induced by streptozotocin treatment (STZ, 250 mg/kg i.v.). 2 weeks later, blood glucose 
concentrations were measured from samples drawn from the tail vein with an Accu-Check 
glucometer (Roche) and further investigations were only performed on animals with blood 
glucose levels higher than 15 mmol/l. Mechanonociceptive thresholds of mice were 
determined by aesthesiometry. 
6. Cisplatin-induced toxic neuropathy: Mice were treated with cisplatin three times a week 
during 5 weeks (2 mg/kg i.p., cumulative dose 30 mg/kg). Mechanonociceptive thresholds 
were measured by aesthesiometry. 
7. Traumatic mononeuropathy induced by partial sciatic nerve lesion: Under anaesthesia 
1/3-1/2 part of the sciatic nerve of mice was ligated unilaterally. Mechanonociceptive 
thresholds were measured by the dynamic plantar aesthesiometer. 
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8. Measurement of plasma somatostatin concentrations in the chronic polyneuropathy 
models: Animals were fastened during a night to ascertain that gastrointestinal somatostatin 
release was minimal. Under anaesthesia arterial blood samples were collected and 
somatostatin concentrations extracted from the plasma were determined by a 
radioimmunoassay (RIA) developed in our department (Németh et al., 1996). The time of 
sampling was chosen to correspond to the period when maximal differences had been found 
between the behavioural thresholds of the two groups of mice.  
RESULTS 
1. PMA test: In wild-type mice (TRPV1+/+) PMA induced an acute nocifensive reaction (paw 
licking and lifting) which lasted from 5-45 min after injection. The total duration of paw 
lickings and liftings was 669.2 ± 170.8 sec. Mice lacking the TRPV1 receptor (TRPV1-/-) did 
not respond to PMA as the duration of the nocifensive reaction did not differ from that evoked 
by the solvent (16.8 ± 8 sec and 20.2 ± 10.3 sec). 
2. Formalin test: Intraplantar injection of formalin induced a two-phase nocifensive reaction 
The total duration of paw lickings and liftings of TRPV1+/+ and TRPV1-/- mice in the first 
phase (0-5 min) were 130.7 ± 12.6 sec and 99.7 ± 16.1 sec, in the second phase (20-45 min) 
268.7 ± 50.7 sec and 363.6.6 ± 37.8 sec, respectively. Statistical analysis revealed no 
significant difference between the two groups in either phase.  
3. Heat injury-induced thermal and mechanical hyperalgesia: Heat thresholds of 
untreated TRPV1+/+ and TRPV1-/-  mice were 44.3 ± 0.4 °C and 44.4 ± 0.3 °C, while their 
mechanonociceptive thresholds were 7.9 ± 0.3 g and 7.5 ± 0.3 g, respectively. There was no 
significant difference therefore between the control values of the two groups. The animals 
recovered from ether anaesthesia within a few minutes after heat injury and showed no signs 
of spontaneous pain. Decreases in the heat and mechanical thresholds were developed 10 and 
20 min following heat injury. Both types of hyperalgesia proved to be significantly reduced in 
TRPV1-/- mice at each measurement point. The maximal drops of heat threshold were 10.23 ± 
1.0 °C and 3.59 ± 0.6 °C, whereas the severest mechanical hyperalgesia values were 56.9 ± 
2.4% and 23.6 ± 7.9% in TRPV1+/+ and TRPV1-/- mice, respectively. 
4. Inflammatory mechanical hyperalgesia evoked by intraplantar carrageenan: The 
control mechanonociceptive thresholds were 7.85 ± 0.2 g in wild-type and 7.31 ± 0.3 g in 
TRPV1 receptor knockout mice. Carrageenan injection resulted in the inflammation of the 
treated limb with visible oedema and redness. 3 hours after treatment mechanical thresholds 
decreased: in TRPV1+/+ mice the threshold dropped to 5.35 ± 0.3 g (31.7 ± 4.1% 
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hyperalgesia), and in TRPV1-/- animals it decreased to 4.9 ± 0.3 g (31.8 ± 6.1% hyperalgesia). 
Therefore, no significant difference was found between the two groups.  
5. Mechanical hyperalgesia in streptozotocin-induced diabetic polyneuropathy: Control 
mechanonociceptive threshold of TRPV1+/+  mice was 6.7 ± 0.2 g, while in the TRPV1-/- 
group it was 6.9 ± 0.3 g. Two weeks following STZ treatment experimental diabetes mellitus 
was present in all mice. In mice lacking the TRPV1 receptor hyperalgesia developed already 
by the 3rd week after treatment and remained significantly more severe compared to wild-type 
mice throughout the whole experimental period lasting until the 7th week. The highest 
difference between the two groups were found on the 5th week (10.29 ± 2.6% hyperalgesia in 
the TRPV1+/+ group and 31.12 ± 2.7% in the TRPV1-/- group). 
6. Mechanical hyperalgesia in cisplatin-induced toxic neuropathy: Mechanonociceptive 
thresholds of cisplatin-treated mice did not change significantly in the first 3 weeks of 
administration (6.6 ± 0.2 g in both groups). In TRPV1-/- mice significant hyperalgesia started 
to develop from the 4th week while in wild-type mice only 4 weeks later. From the 8th week, 
however, there was no significant difference between the two groups. The maximal difference 
was measured on the 7th week (2.64 ± 4.0% hyperalgesia in the TRPV1+/+ group and 7.87 ± 
3.6% in the TRPV1-/- group). 
7. Mechanical hyperalgesia in traumatic neuropathy: One week after partial sciatic nerve 
lesion mechanical hyperalgesia developed on the operated limb which was maintained 
throughout the 5-week experimental period. The highest values were measured on the 2nd 
week when hyperalgesia was 45.13 ± 4.7% in TRPV1+/+ and 40.53 ± 4.0% in TRPV1-/- 
animals. No significant differences were found between wild-type and gene-deleted mice at 
any measurement points.  
8. Plasma somatostatin concentrations in the chronic polyneuropathy models: Plasma 
somatostatin concentrations of naïve mice were 8.5 ± 0.2 fmol/ml in the TRPV1+/+ group and 
7.44 ± 0.6 fmol/ml in TRPV1-/- mice. Blood sampling of neuropathic mice was performed 5 
weeks after STZ injection and 7 weeks following the beginning of cisplatin treatment, when 
maximal differences were observed between the mechanical hyperalgesia of the two groups. 
Plasma somatostatin levels of neuropathic TRPV1+/+ mice were significantly elevated 
compared to naïve mice, both in diabetic (10.08 ± 0.6 fmol/ml) and cisplatin-treated animals 
(10.46 ± 0.9 fmol/ml). On the contrary, no increase was found in TRPV1-/- mice, plasma 
somatostatin levels were 8.02 ± 0.6 fmol/ml and 7.63 ± 0.5 fmol/ml, respectively. 
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CONCLUSIONS 
With the investigation of TRPV1 receptor gene deficient mice we have demonstrated that this 
noxious stimulus-gated ion channel is essential in phorbolesther-induced acute 
chemonociception and in heat and mechanical hyperalgesia developed after mild heat injury. 
Neither formalin-induced nocifensive behaviour, nor mechanical hyperalgesia in carrageenan-
inflammation or traumatic mononeuropathy were influenced by the lack of TRPV1 receptor. 
In chronic diabetic and toxic polyneuropathy it had a protective role as mechanical 
hyperalgesia was less severe and developed later in its presence. There are several pieces of 
evidence concerning that somatostatin released from capsaicin-sensitive neurons has systemic 
anti-inflammatory and antinociceptive effect (Szolcsányi et al., 1998a,b; Helyes et al., 2000; 
Carlton et al., 2001a,b; 2003; Helyes et al., 2004). Our hypothesis was that in polyneuropathic 
conditions the somatostatin-mediated counter-regulatory mechanism is activated by TRPV1 
stimulation and its absence leads to the earlier onset and increase in the severity of 
hyperalgesia. This could be confirmed by the results of plasma somatostatin concentrations 
which showed that in wild-type mice somatostatin was increased in polyneuropathic 
compared to untreated controls, while in TRPV1-/- mice the concentration of the peptide 
remained unaltered. 
In conclusion, in certain models TRPV1 receptor promotes nociception but surprisingly, in 
chronic polyneuropathy models it mediates an opposite, antinociceptive effect, possibly by 
the release of somatostatin. In the models where no difference was found in the behaviour of 
TRPV-/- mice, the receptor is not likely to play a key role, but it is also possible that the two 
opposing effects extinguish each other. As two contrary functions of TRPV1 receptor were 
revealed in the investigated models, it is concluded that both antagonists and agonists may 
have therapeutic value depending on the pathomechanism of the given condition. 
 
IV. DEVELOPMENT OF A HEAT INJURY-INDUCED THERMAL HYPERALGESIA 
MODEL EMPLOYING A NOVEL INCREASING-TEMPERATURE WATER BATH 
 
Conventional tests of thermonociception are based on exposing the animal’s paw or tail to a 
heat stimulus of constant, suprathreshold intensity, e.g. by placing it on a hot metal surface 
(constant temperature hot plate) or stimulating it with a focused beam of light (Hargreaves’ 
plantar test), and the time until the appearance of a nocifensive reaction is determined (Le 
Bars et al., 2001). This latency is considered, not quite consequently, as noxious heat 
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threshold. The disadvantage of these methods is that upon repeated measurements latency 
may decrease or increase due to sensitization or habituation and it is not less important that 
only the effect of opioid analgesics can be reliably detected. A further drawback is that 
latency values are difficult to compare to heat thresholds routinely determined in 
electrophysiological experiments (e.g. patch clamp, single fibre recordings). 
Applying an increasing heat stimulus, the noxious heat threshold temperature of animals can 
be measured i.e. the lowest temperature which evokes a nocifensive reaction. Our research 
group has successfully implemented this measurement principle by developing an increasing-
temperature hot plate and a new hyperalgesia model (Almási et al., 2003) which was suitable 
to detect the antinociceptive and antihyperalgesic effect of low doses of morphine, diclofenac 
and paracetamol. Besides its excellent pharmacological sensitivity, threshold measurement 
also complies better with the international ethical guidelines (Zimmermann, 1983), as animals 
are exposed to the least and shortest possible painful stimuli. In the present experiments 
another newly developed equipment, the increasing-temperature water bath was used.  
METHODS 
1. Determination of the noxious heat threshold with the increasing-temperature water 
bath: The increasing-temperature water bath was developed in cooperation with Experimetria 
Ltd. (Budapest). The equipment consists of a water container with a built-in heating unit and a 
separate controlling unit for setting different heating rates and starting temperatures which 
also has a display showing the actual temperature of the water bath. Rats were lightly 
restrained and held in an upright position above the water bath allowing free movement of the 
hind limbs, then one of the hind paws was immersed into the water and the heating process 
was started afterwards. A starting temperature of 30 °C and a heating rate of 24 °C/min were 
employed at each measurement. At the moment when the animal withdrew its paw the heating 
was immediately stopped and the corresponding temperature was recorded as the noxious heat 
threshold of the examined paw. 
2. Induction of thermal hyperalgesia by mild heat injury and assessment of the 
antihyperalgesic effect of analgesics: Following control measurements, under ether 
anaesthesia one of the hind paws was immersed in a 51 °C hot water bath for 20 seconds. 
After recovering from anaesthesia, heat threshold determinations were repeated 10 and 20 
minutes after heat injury to confirm the development of hyperalgesia. Drugs were 
administered after the 20-minute measurement which was followed by repeated 
measurements at 10 minute intervals. In each measurement series, one half of the group was 
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injected with the solvent and drug effects were assessed compared to the solvent-treated 
group. 
RESULTS 
The noxious heat threshold of untreated rats was 43.1 ± 0.4 °C and was reproducible upon 
measurements at intervals of 10 minutes which means that no significant difference was 
found between thresholds of the same paw measured at different time points. Upon heat 
threshold measurements 10 and 20 min following heat injury, a 7−8 °C drop of the threshold 
was observed and this heat hyperalgesia was maintained at an even level for at least an hour. 
Morphine, non selective cyclooxygenase inhibitors diclofenac and ibuprofen or centrally- 
acting paracetamol administered after the 20-min measurement all dose-dependently reduced 
the heat injury-induced drop of heat threshold (minimal effective doses (MED): 0.3; 0.3; 10; 
30 mg/kg i.p.). The model was suitable for showing the effect of the peripherally-acting 
somatostatin receptor agonist TT-232 (MED: 0.1 mg/kg i.p). Intraplantar injection of 
morphine (10 µg), diclofenac (10 µg) and ibuprofen (100 µg) administered 20 minutes after 
heat injury all significantly decreased subsequent thermal hyperalgesia Lipoxygenase 
inhibitor nordihydroguaiaretic acid (NDGA, 10 mg/kg i.p.) failed to influence thermal 
hyperalgesia, bradikinin B2 receptor antagonist HOE140 (0.1 mg/kg i.p.), however, had a 
significant inhibitory effect, while the TRPV1 receptor antagonist JYL1421 (2 mg/kg i.p.) 
almost completely abolished the drop of heat threshold. 
CONCLUSIONS 
The increasing-temperature water bath was suitable for the reliable and reproducible 
measurement of the noxious heat threshold of conscious rats. Heat injury, as a naturally 
occurring noxious impact was used to induce hyperalgesia, in other words, a first degree burn 
was modelled which led to a pronounced drop of heat threshold. When examining drug 
effects, the common clinical practice was followed by administrating the compounds after the 
injury, contrary to typical experimental protocols where pretreatments are performed. The 
model proved to be remarkably sensitive to the antihyperalgesic effect of both morphine and 
cyclooxygenase inhibitors and besides the conventional analgesics, it was suitable to show the 
effect of a compound of a novel target of action, the somatostatin receptor agonist TT-232 
(see chapter II). Human doses calculated on the basis of the minimal effective doses obtained 
with our model are in the range of the recommended doses applied in the clinical practice. 
The model was also able to detect the effect of locally applied analgesics.  
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Investigating the pathomechanism of heat injury-induced thermal hyperalgesia we have 
concluded that prostaglandins definitely played an important role as cyclooxygenase 
inhibitors inhibited hyperalgesia at low doses and after local treatment as well. We have 
proven that bradikinin had a major part in the development of heat injury-induced drop of 
heat threshold and furthermore, activation and sensitization of the TRPV1 receptor was 
essential in this thermal hyperalgesia. The latter finding is also supported by our results 
gained with TRPV1 receptor gene-deleted mice (see chapter III). Lipoxygenase inhibition 
proved to be ineffective in our model which means that lipoxygenase products are either not 
formed in tissue injury following mild burns or their effect is minor so that its abolishment 
does not have an impact on hyperalgesia.  
In conclusion, the thermonociceptive test developed and validated in our laboratories is a 
reliable, easily performed and sensitive new method which is suitable for the investigation of 
peripherally and centrally-acting analgesics. At the same time, heat injury-induced drop of 
heat threshold is an excellent in vivo model for the examination of the pathomechanism of 
thermal hyperalgesia.  
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SUMMARY OF THE NEW FINDINGS PRESENTED IN THE THESIS 
 
1. Our results have proven that anandamide and palmitoyl-ethanolamide – naturally 
occurring CB1 and CB2 receptor agonists – decreased sensory neuropeptide release in 
vivo induced by the TRPV1 receptor agonist resiniferatoxin. We have shown that 
anandamide and palmitoyl-ethanolamide diminished partial sciatic nerve lesion-induced 
mechanical hyperalgesia as well, via CB1 and CB2 receptor activation. CB1 and/or CB2 
receptor antagonists enhanced mechanical hyperalgesia in vivo, therefore it is suggested that 
endogenous cannabinoids exert a tonic antinociceptive effect in traumatic mechanical 
hyperalgesia. 
2. We have demonstrated that the somatostatin receptor agonist TT-232 is a potent 
antinociceptive and antihyperalgesic compound in acute chemical and thermal nociceptive 
models and chronic diabetic polyneuropathy.  
3. Using gene-deleted mice it has been shown that in certain acute pain models the 
presence of TRPV1 receptor was indispensable while in others it had no exclusive role, 
however, in chronic polyneuropathy models the absence of the receptor surprisingly 
enhanced mechanical hyperalgesia. We have hypothesized that as a consequence of chronic 
stimulation of TRPV1 receptor counter-regulatory processes could be initiated mediated 
by systemic action of somatostatin released from TRPV1 receptor-expressing nerve 
endings. The TRPV1 receptor may mediate pronociceptive and antinociceptive effects 
depending on the pathophysiological process, therefore both agonists and antagonists may 
be drug candidates.  
4. We have elaborated a new thermonociceptive test, the heat injury-induced thermal 
hyperalgesia model based on a self-developed method measuring the noxious heat 
threshold, which proved to be a very reliable and sensitive method for detecting the 
antihyperalgesic action of compounds that act on different targets. Upon examination of 
the pathomechanism of thermal hyperalgesia we have concluded that the formation of 
cyclooxygenase products and bradikinin as well as the TRPV1 receptor played 
important role in the development of heat threshold drop.  
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